Pharma & Healthcare
Global Targeted Drugs for Parkinson's Disease Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 560462
- Pages: 102
- Figures: 103
- Views: 1
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Targeted Drugs for Parkinson's Disease market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Acadia Pharmaceuticals Inc.
Kyowa Kirin
Supernus Pharmaceuticals
UCB
Sumitomo Pharma Co., Ltd.
Segment by Type
Capsule
Patch
Other
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Targeted Drugs for Parkinson's Disease study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Targeted Drugs for Parkinson's Disease market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Acadia Pharmaceuticals Inc.
Kyowa Kirin
Supernus Pharmaceuticals
UCB
Sumitomo Pharma Co., Ltd.
Segment by Type
Capsule
Patch
Other
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Targeted Drugs for Parkinson's Disease study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Targeted Drugs for Parkinson's Disease: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Targeted Drugs for Parkinson's Disease Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Capsule
1.2.3 Patch
1.2.4 Other
1.3 Market Segmentation by Application
1.3.1 Global Targeted Drugs for Parkinson's Disease Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Targeted Drugs for Parkinson's Disease Revenue Estimates and Forecasts 2020-2031
2.2 Global Targeted Drugs for Parkinson's Disease Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Targeted Drugs for Parkinson's Disease Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Targeted Drugs for Parkinson's Disease Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Capsule Market Size by Players
3.3.2 Patch Market Size by Players
3.3.3 Other Market Size by Players
3.4 Global Targeted Drugs for Parkinson's Disease Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Targeted Drugs for Parkinson's Disease Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Targeted Drugs for Parkinson's Disease Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Targeted Drugs for Parkinson's Disease Market Size by Type (2020-2031)
6.4 North America Targeted Drugs for Parkinson's Disease Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Targeted Drugs for Parkinson's Disease Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Targeted Drugs for Parkinson's Disease Market Size by Type (2020-2031)
7.4 Europe Targeted Drugs for Parkinson's Disease Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Targeted Drugs for Parkinson's Disease Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size by Type (2020-2031)
8.4 Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Targeted Drugs for Parkinson's Disease Market Size by Type (2020-2031)
9.4 Central and South America Targeted Drugs for Parkinson's Disease Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Targeted Drugs for Parkinson's Disease Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Targeted Drugs for Parkinson's Disease Market Size by Type (2020-2031)
10.4 Middle East and Africa Targeted Drugs for Parkinson's Disease Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Targeted Drugs for Parkinson's Disease Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Acadia Pharmaceuticals Inc.
11.1.1 Acadia Pharmaceuticals Inc. Corporation Information
11.1.2 Acadia Pharmaceuticals Inc. Business Overview
11.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Product Features and Attributes
11.1.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
11.1.5 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Revenue by Product in 2024
11.1.6 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Revenue by Application in 2024
11.1.7 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Revenue by Geographic Area in 2024
11.1.8 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease SWOT Analysis
11.1.9 Acadia Pharmaceuticals Inc. Recent Developments
11.2 Kyowa Kirin
11.2.1 Kyowa Kirin Corporation Information
11.2.2 Kyowa Kirin Business Overview
11.2.3 Kyowa Kirin Targeted Drugs for Parkinson's Disease Product Features and Attributes
11.2.4 Kyowa Kirin Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
11.2.5 Kyowa Kirin Targeted Drugs for Parkinson's Disease Revenue by Product in 2024
11.2.6 Kyowa Kirin Targeted Drugs for Parkinson's Disease Revenue by Application in 2024
11.2.7 Kyowa Kirin Targeted Drugs for Parkinson's Disease Revenue by Geographic Area in 2024
11.2.8 Kyowa Kirin Targeted Drugs for Parkinson's Disease SWOT Analysis
11.2.9 Kyowa Kirin Recent Developments
11.3 Supernus Pharmaceuticals
11.3.1 Supernus Pharmaceuticals Corporation Information
11.3.2 Supernus Pharmaceuticals Business Overview
11.3.3 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Product Features and Attributes
11.3.4 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
11.3.5 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Revenue by Product in 2024
11.3.6 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Revenue by Application in 2024
11.3.7 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Revenue by Geographic Area in 2024
11.3.8 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease SWOT Analysis
11.3.9 Supernus Pharmaceuticals Recent Developments
11.4 UCB
11.4.1 UCB Corporation Information
11.4.2 UCB Business Overview
11.4.3 UCB Targeted Drugs for Parkinson's Disease Product Features and Attributes
11.4.4 UCB Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
11.4.5 UCB Targeted Drugs for Parkinson's Disease Revenue by Product in 2024
11.4.6 UCB Targeted Drugs for Parkinson's Disease Revenue by Application in 2024
11.4.7 UCB Targeted Drugs for Parkinson's Disease Revenue by Geographic Area in 2024
11.4.8 UCB Targeted Drugs for Parkinson's Disease SWOT Analysis
11.4.9 UCB Recent Developments
11.5 Sumitomo Pharma Co., Ltd.
11.5.1 Sumitomo Pharma Co., Ltd. Corporation Information
11.5.2 Sumitomo Pharma Co., Ltd. Business Overview
11.5.3 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Product Features and Attributes
11.5.4 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
11.5.5 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Revenue by Product in 2024
11.5.6 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Revenue by Application in 2024
11.5.7 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Revenue by Geographic Area in 2024
11.5.8 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease SWOT Analysis
11.5.9 Sumitomo Pharma Co., Ltd. Recent Developments
12 Targeted Drugs for Parkinson's DiseaseIndustry Chain Analysis
12.1 Targeted Drugs for Parkinson's Disease Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Targeted Drugs for Parkinson's Disease Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Targeted Drugs for Parkinson's Disease Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Targeted Drugs for Parkinson's Disease: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Targeted Drugs for Parkinson's Disease Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Capsule
1.2.3 Patch
1.2.4 Other
1.3 Market Segmentation by Application
1.3.1 Global Targeted Drugs for Parkinson's Disease Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Targeted Drugs for Parkinson's Disease Revenue Estimates and Forecasts 2020-2031
2.2 Global Targeted Drugs for Parkinson's Disease Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Targeted Drugs for Parkinson's Disease Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Targeted Drugs for Parkinson's Disease Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Capsule Market Size by Players
3.3.2 Patch Market Size by Players
3.3.3 Other Market Size by Players
3.4 Global Targeted Drugs for Parkinson's Disease Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Targeted Drugs for Parkinson's Disease Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Targeted Drugs for Parkinson's Disease Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Targeted Drugs for Parkinson's Disease Market Size by Type (2020-2031)
6.4 North America Targeted Drugs for Parkinson's Disease Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Targeted Drugs for Parkinson's Disease Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Targeted Drugs for Parkinson's Disease Market Size by Type (2020-2031)
7.4 Europe Targeted Drugs for Parkinson's Disease Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Targeted Drugs for Parkinson's Disease Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size by Type (2020-2031)
8.4 Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Targeted Drugs for Parkinson's Disease Market Size by Type (2020-2031)
9.4 Central and South America Targeted Drugs for Parkinson's Disease Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Targeted Drugs for Parkinson's Disease Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Targeted Drugs for Parkinson's Disease Market Size by Type (2020-2031)
10.4 Middle East and Africa Targeted Drugs for Parkinson's Disease Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Targeted Drugs for Parkinson's Disease Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Acadia Pharmaceuticals Inc.
11.1.1 Acadia Pharmaceuticals Inc. Corporation Information
11.1.2 Acadia Pharmaceuticals Inc. Business Overview
11.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Product Features and Attributes
11.1.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
11.1.5 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Revenue by Product in 2024
11.1.6 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Revenue by Application in 2024
11.1.7 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Revenue by Geographic Area in 2024
11.1.8 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease SWOT Analysis
11.1.9 Acadia Pharmaceuticals Inc. Recent Developments
11.2 Kyowa Kirin
11.2.1 Kyowa Kirin Corporation Information
11.2.2 Kyowa Kirin Business Overview
11.2.3 Kyowa Kirin Targeted Drugs for Parkinson's Disease Product Features and Attributes
11.2.4 Kyowa Kirin Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
11.2.5 Kyowa Kirin Targeted Drugs for Parkinson's Disease Revenue by Product in 2024
11.2.6 Kyowa Kirin Targeted Drugs for Parkinson's Disease Revenue by Application in 2024
11.2.7 Kyowa Kirin Targeted Drugs for Parkinson's Disease Revenue by Geographic Area in 2024
11.2.8 Kyowa Kirin Targeted Drugs for Parkinson's Disease SWOT Analysis
11.2.9 Kyowa Kirin Recent Developments
11.3 Supernus Pharmaceuticals
11.3.1 Supernus Pharmaceuticals Corporation Information
11.3.2 Supernus Pharmaceuticals Business Overview
11.3.3 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Product Features and Attributes
11.3.4 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
11.3.5 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Revenue by Product in 2024
11.3.6 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Revenue by Application in 2024
11.3.7 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Revenue by Geographic Area in 2024
11.3.8 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease SWOT Analysis
11.3.9 Supernus Pharmaceuticals Recent Developments
11.4 UCB
11.4.1 UCB Corporation Information
11.4.2 UCB Business Overview
11.4.3 UCB Targeted Drugs for Parkinson's Disease Product Features and Attributes
11.4.4 UCB Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
11.4.5 UCB Targeted Drugs for Parkinson's Disease Revenue by Product in 2024
11.4.6 UCB Targeted Drugs for Parkinson's Disease Revenue by Application in 2024
11.4.7 UCB Targeted Drugs for Parkinson's Disease Revenue by Geographic Area in 2024
11.4.8 UCB Targeted Drugs for Parkinson's Disease SWOT Analysis
11.4.9 UCB Recent Developments
11.5 Sumitomo Pharma Co., Ltd.
11.5.1 Sumitomo Pharma Co., Ltd. Corporation Information
11.5.2 Sumitomo Pharma Co., Ltd. Business Overview
11.5.3 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Product Features and Attributes
11.5.4 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
11.5.5 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Revenue by Product in 2024
11.5.6 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Revenue by Application in 2024
11.5.7 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Revenue by Geographic Area in 2024
11.5.8 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease SWOT Analysis
11.5.9 Sumitomo Pharma Co., Ltd. Recent Developments
12 Targeted Drugs for Parkinson's DiseaseIndustry Chain Analysis
12.1 Targeted Drugs for Parkinson's Disease Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Targeted Drugs for Parkinson's Disease Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Targeted Drugs for Parkinson's Disease Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Targeted Drugs for Parkinson's Disease Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Targeted Drugs for Parkinson's Disease Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Targeted Drugs for Parkinson's Disease Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Targeted Drugs for Parkinson's Disease Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Targeted Drugs for Parkinson's Disease Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Targeted Drugs for Parkinson's Disease Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Targeted Drugs for Parkinson's Disease Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Targeted Drugs for Parkinson's Disease by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Parkinson's Disease as of 2024)
Table 11. Global Targeted Drugs for Parkinson's Disease Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Targeted Drugs for Parkinson's Disease Companies Headquarters
Table 13. Global Targeted Drugs for Parkinson's Disease Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Targeted Drugs for Parkinson's Disease Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Targeted Drugs for Parkinson's Disease Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Targeted Drugs for Parkinson's Disease Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Targeted Drugs for Parkinson's Disease Revenue by Application (2026-2031) & (US$ Million)
Table 21. Targeted Drugs for Parkinson's Disease High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Targeted Drugs for Parkinson's Disease Growth Accelerators and Market Barriers
Table 25. North America Targeted Drugs for Parkinson's Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Targeted Drugs for Parkinson's Disease Growth Accelerators and Market Barriers
Table 27. Europe Targeted Drugs for Parkinson's Disease Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Targeted Drugs for Parkinson's Disease Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Targeted Drugs for Parkinson's Disease Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Targeted Drugs for Parkinson's Disease Investment Opportunities and Key Challenges
Table 31. Central and South America Targeted Drugs for Parkinson's Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Targeted Drugs for Parkinson's Disease Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Targeted Drugs for Parkinson's Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Acadia Pharmaceuticals Inc. Corporation Information
Table 35. Acadia Pharmaceuticals Inc. Description and Major Businesses
Table 36. Acadia Pharmaceuticals Inc. Product Features and Attributes
Table 37. Acadia Pharmaceuticals Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Acadia Pharmaceuticals Inc. Revenue Proportion by Product in 2024
Table 39. Acadia Pharmaceuticals Inc. Revenue Proportion by Application in 2024
Table 40. Acadia Pharmaceuticals Inc. Revenue Proportion by Geographic Area in 2024
Table 41. Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease SWOT Analysis
Table 42. Acadia Pharmaceuticals Inc. Recent Developments
Table 43. Kyowa Kirin Corporation Information
Table 44. Kyowa Kirin Description and Major Businesses
Table 45. Kyowa Kirin Product Features and Attributes
Table 46. Kyowa Kirin Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Kyowa Kirin Revenue Proportion by Product in 2024
Table 48. Kyowa Kirin Revenue Proportion by Application in 2024
Table 49. Kyowa Kirin Revenue Proportion by Geographic Area in 2024
Table 50. Kyowa Kirin Targeted Drugs for Parkinson's Disease SWOT Analysis
Table 51. Kyowa Kirin Recent Developments
Table 52. Supernus Pharmaceuticals Corporation Information
Table 53. Supernus Pharmaceuticals Description and Major Businesses
Table 54. Supernus Pharmaceuticals Product Features and Attributes
Table 55. Supernus Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Supernus Pharmaceuticals Revenue Proportion by Product in 2024
Table 57. Supernus Pharmaceuticals Revenue Proportion by Application in 2024
Table 58. Supernus Pharmaceuticals Revenue Proportion by Geographic Area in 2024
Table 59. Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease SWOT Analysis
Table 60. Supernus Pharmaceuticals Recent Developments
Table 61. UCB Corporation Information
Table 62. UCB Description and Major Businesses
Table 63. UCB Product Features and Attributes
Table 64. UCB Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. UCB Revenue Proportion by Product in 2024
Table 66. UCB Revenue Proportion by Application in 2024
Table 67. UCB Revenue Proportion by Geographic Area in 2024
Table 68. UCB Targeted Drugs for Parkinson's Disease SWOT Analysis
Table 69. UCB Recent Developments
Table 70. Sumitomo Pharma Co., Ltd. Corporation Information
Table 71. Sumitomo Pharma Co., Ltd. Description and Major Businesses
Table 72. Sumitomo Pharma Co., Ltd. Product Features and Attributes
Table 73. Sumitomo Pharma Co., Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Sumitomo Pharma Co., Ltd. Revenue Proportion by Product in 2024
Table 75. Sumitomo Pharma Co., Ltd. Revenue Proportion by Application in 2024
Table 76. Sumitomo Pharma Co., Ltd. Revenue Proportion by Geographic Area in 2024
Table 77. Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease SWOT Analysis
Table 78. Sumitomo Pharma Co., Ltd. Recent Developments
Table 79. Raw Materials Key Suppliers
Table 80. Distributors List
Table 81. Market Trends and Market Evolution
Table 82. Market Drivers and Opportunities
Table 83. Market Challenges, Risks, and Restraints
Table 84. Research Programs/Design for This Report
Table 85. Key Data Information from Secondary Sources
Table 86. Key Data Information from Primary Sources
List of Figures
Figure 1. Targeted Drugs for Parkinson's Disease Product Picture
Figure 2. Global Targeted Drugs for Parkinson's Disease Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Capsule Product Picture
Figure 4. Patch Product Picture
Figure 5. Other Product Picture
Figure 6. Global Targeted Drugs for Parkinson's Disease Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Clinic
Figure 9. Other
Figure 10. Targeted Drugs for Parkinson's Disease Report Years Considered
Figure 11. Global Targeted Drugs for Parkinson's Disease Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 13. Global Targeted Drugs for Parkinson's Disease Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Targeted Drugs for Parkinson's Disease Revenue Market Share by Region (2020-2031)
Figure 15. Global Targeted Drugs for Parkinson's Disease Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. Capsule Revenue Market Share by Player in 2024
Figure 18. Patch Revenue Market Share by Player in 2024
Figure 19. Other Revenue Market Share by Player in 2024
Figure 20. Global Targeted Drugs for Parkinson's Disease Revenue Market Share by Type (2020-2031)
Figure 21. Global Targeted Drugs for Parkinson's Disease Revenue Market Share by Application (2020-2031)
Figure 22. North America Targeted Drugs for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 23. North America Top 5 Players Targeted Drugs for Parkinson's Disease Revenue (US$ Million) in 2024
Figure 24. North America Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Type (2020 - 2031)
Figure 25. North America Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Application (2020-2031)
Figure 26. US Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 27. Canada Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 28. Mexico Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 29. Europe Targeted Drugs for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 30. Europe Top 5 Players Targeted Drugs for Parkinson's Disease Revenue (US$ Million) in 2024
Figure 31. Europe Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Type (2020-2031)
Figure 32. Europe Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Application (2020-2031)
Figure 33. Germany Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 34. France Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 35. U.K. Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 36. Italy Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 37. Russia Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Targeted Drugs for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Top 8 Players Targeted Drugs for Parkinson's Disease Revenue (US$ Million) in 2024
Figure 40. Asia-Pacific Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Type (2020-2031)
Figure 41. Asia-Pacific Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Application (2020-2031)
Figure 42. Indonesia Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 43. Japan Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 44. South Korea Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 45. Australia Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 46. India Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 47. Indonesia Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 48. Vietnam Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 49. Malaysia Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 50. Philippines Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 51. Singapore Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 52. Central and South America Targeted Drugs for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Central and South America Top 5 Players Targeted Drugs for Parkinson's Disease Revenue (US$ Million) in 2024
Figure 54. Central and South America Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Type (2020-2031)
Figure 55. Central and South America Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Application (2020-2031)
Figure 56. Brazil Targeted Drugs for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
Figure 57. Argentina Targeted Drugs for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
Figure 58. Middle East and Africa Targeted Drugs for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Middle East and Africa Top 5 Players Targeted Drugs for Parkinson's Disease Revenue (US$ Million) in 2024
Figure 60. South America Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Type (2020-2031)
Figure 61. Middle East and Africa Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Application (2020-2031)
Figure 62. GCC Countries Targeted Drugs for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
Figure 63. Israel Targeted Drugs for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
Figure 64. Egypt Targeted Drugs for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
Figure 65. South Africa Targeted Drugs for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
Figure 66. Targeted Drugs for Parkinson's Disease Industry Chain Mapping
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Table 1. Global Targeted Drugs for Parkinson's Disease Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Targeted Drugs for Parkinson's Disease Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Targeted Drugs for Parkinson's Disease Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Targeted Drugs for Parkinson's Disease Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Targeted Drugs for Parkinson's Disease Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Targeted Drugs for Parkinson's Disease Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Targeted Drugs for Parkinson's Disease Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Targeted Drugs for Parkinson's Disease by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Parkinson's Disease as of 2024)
Table 11. Global Targeted Drugs for Parkinson's Disease Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Targeted Drugs for Parkinson's Disease Companies Headquarters
Table 13. Global Targeted Drugs for Parkinson's Disease Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Targeted Drugs for Parkinson's Disease Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Targeted Drugs for Parkinson's Disease Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Targeted Drugs for Parkinson's Disease Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Targeted Drugs for Parkinson's Disease Revenue by Application (2026-2031) & (US$ Million)
Table 21. Targeted Drugs for Parkinson's Disease High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Targeted Drugs for Parkinson's Disease Growth Accelerators and Market Barriers
Table 25. North America Targeted Drugs for Parkinson's Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Targeted Drugs for Parkinson's Disease Growth Accelerators and Market Barriers
Table 27. Europe Targeted Drugs for Parkinson's Disease Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Targeted Drugs for Parkinson's Disease Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Targeted Drugs for Parkinson's Disease Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Targeted Drugs for Parkinson's Disease Investment Opportunities and Key Challenges
Table 31. Central and South America Targeted Drugs for Parkinson's Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Targeted Drugs for Parkinson's Disease Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Targeted Drugs for Parkinson's Disease Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Acadia Pharmaceuticals Inc. Corporation Information
Table 35. Acadia Pharmaceuticals Inc. Description and Major Businesses
Table 36. Acadia Pharmaceuticals Inc. Product Features and Attributes
Table 37. Acadia Pharmaceuticals Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Acadia Pharmaceuticals Inc. Revenue Proportion by Product in 2024
Table 39. Acadia Pharmaceuticals Inc. Revenue Proportion by Application in 2024
Table 40. Acadia Pharmaceuticals Inc. Revenue Proportion by Geographic Area in 2024
Table 41. Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease SWOT Analysis
Table 42. Acadia Pharmaceuticals Inc. Recent Developments
Table 43. Kyowa Kirin Corporation Information
Table 44. Kyowa Kirin Description and Major Businesses
Table 45. Kyowa Kirin Product Features and Attributes
Table 46. Kyowa Kirin Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Kyowa Kirin Revenue Proportion by Product in 2024
Table 48. Kyowa Kirin Revenue Proportion by Application in 2024
Table 49. Kyowa Kirin Revenue Proportion by Geographic Area in 2024
Table 50. Kyowa Kirin Targeted Drugs for Parkinson's Disease SWOT Analysis
Table 51. Kyowa Kirin Recent Developments
Table 52. Supernus Pharmaceuticals Corporation Information
Table 53. Supernus Pharmaceuticals Description and Major Businesses
Table 54. Supernus Pharmaceuticals Product Features and Attributes
Table 55. Supernus Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Supernus Pharmaceuticals Revenue Proportion by Product in 2024
Table 57. Supernus Pharmaceuticals Revenue Proportion by Application in 2024
Table 58. Supernus Pharmaceuticals Revenue Proportion by Geographic Area in 2024
Table 59. Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease SWOT Analysis
Table 60. Supernus Pharmaceuticals Recent Developments
Table 61. UCB Corporation Information
Table 62. UCB Description and Major Businesses
Table 63. UCB Product Features and Attributes
Table 64. UCB Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. UCB Revenue Proportion by Product in 2024
Table 66. UCB Revenue Proportion by Application in 2024
Table 67. UCB Revenue Proportion by Geographic Area in 2024
Table 68. UCB Targeted Drugs for Parkinson's Disease SWOT Analysis
Table 69. UCB Recent Developments
Table 70. Sumitomo Pharma Co., Ltd. Corporation Information
Table 71. Sumitomo Pharma Co., Ltd. Description and Major Businesses
Table 72. Sumitomo Pharma Co., Ltd. Product Features and Attributes
Table 73. Sumitomo Pharma Co., Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Sumitomo Pharma Co., Ltd. Revenue Proportion by Product in 2024
Table 75. Sumitomo Pharma Co., Ltd. Revenue Proportion by Application in 2024
Table 76. Sumitomo Pharma Co., Ltd. Revenue Proportion by Geographic Area in 2024
Table 77. Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease SWOT Analysis
Table 78. Sumitomo Pharma Co., Ltd. Recent Developments
Table 79. Raw Materials Key Suppliers
Table 80. Distributors List
Table 81. Market Trends and Market Evolution
Table 82. Market Drivers and Opportunities
Table 83. Market Challenges, Risks, and Restraints
Table 84. Research Programs/Design for This Report
Table 85. Key Data Information from Secondary Sources
Table 86. Key Data Information from Primary Sources
List of Figures
Figure 1. Targeted Drugs for Parkinson's Disease Product Picture
Figure 2. Global Targeted Drugs for Parkinson's Disease Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Capsule Product Picture
Figure 4. Patch Product Picture
Figure 5. Other Product Picture
Figure 6. Global Targeted Drugs for Parkinson's Disease Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Clinic
Figure 9. Other
Figure 10. Targeted Drugs for Parkinson's Disease Report Years Considered
Figure 11. Global Targeted Drugs for Parkinson's Disease Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 13. Global Targeted Drugs for Parkinson's Disease Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Targeted Drugs for Parkinson's Disease Revenue Market Share by Region (2020-2031)
Figure 15. Global Targeted Drugs for Parkinson's Disease Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. Capsule Revenue Market Share by Player in 2024
Figure 18. Patch Revenue Market Share by Player in 2024
Figure 19. Other Revenue Market Share by Player in 2024
Figure 20. Global Targeted Drugs for Parkinson's Disease Revenue Market Share by Type (2020-2031)
Figure 21. Global Targeted Drugs for Parkinson's Disease Revenue Market Share by Application (2020-2031)
Figure 22. North America Targeted Drugs for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 23. North America Top 5 Players Targeted Drugs for Parkinson's Disease Revenue (US$ Million) in 2024
Figure 24. North America Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Type (2020 - 2031)
Figure 25. North America Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Application (2020-2031)
Figure 26. US Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 27. Canada Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 28. Mexico Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 29. Europe Targeted Drugs for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 30. Europe Top 5 Players Targeted Drugs for Parkinson's Disease Revenue (US$ Million) in 2024
Figure 31. Europe Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Type (2020-2031)
Figure 32. Europe Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Application (2020-2031)
Figure 33. Germany Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 34. France Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 35. U.K. Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 36. Italy Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 37. Russia Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Targeted Drugs for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Top 8 Players Targeted Drugs for Parkinson's Disease Revenue (US$ Million) in 2024
Figure 40. Asia-Pacific Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Type (2020-2031)
Figure 41. Asia-Pacific Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Application (2020-2031)
Figure 42. Indonesia Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 43. Japan Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 44. South Korea Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 45. Australia Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 46. India Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 47. Indonesia Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 48. Vietnam Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 49. Malaysia Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 50. Philippines Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 51. Singapore Targeted Drugs for Parkinson's Disease Revenue (2020-2031) & (US$ Million)
Figure 52. Central and South America Targeted Drugs for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Central and South America Top 5 Players Targeted Drugs for Parkinson's Disease Revenue (US$ Million) in 2024
Figure 54. Central and South America Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Type (2020-2031)
Figure 55. Central and South America Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Application (2020-2031)
Figure 56. Brazil Targeted Drugs for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
Figure 57. Argentina Targeted Drugs for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
Figure 58. Middle East and Africa Targeted Drugs for Parkinson's Disease Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Middle East and Africa Top 5 Players Targeted Drugs for Parkinson's Disease Revenue (US$ Million) in 2024
Figure 60. South America Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Type (2020-2031)
Figure 61. Middle East and Africa Targeted Drugs for Parkinson's Disease Revenue (US$ Million) by Application (2020-2031)
Figure 62. GCC Countries Targeted Drugs for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
Figure 63. Israel Targeted Drugs for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
Figure 64. Egypt Targeted Drugs for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
Figure 65. South Africa Targeted Drugs for Parkinson's Disease Revenue (2020-2025) & (US$ Million)
Figure 66. Targeted Drugs for Parkinson's Disease Industry Chain Mapping
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232